pharma news, views and analysis

in News
After false start, Merck claims Keytruda approval in early breast cancer
July 28, 2021 Share
X
After false start, Merck claims Keytruda approval in early breast cancer
https://pharmaphorum.com/news/after-false-start-merck-claims-keytruda-approval-in-early-breast-cancer/
in News
BMS pulls speedy Opdivo approval for liver cancer in US
July 26, 2021 Share
X
BMS pulls speedy Opdivo approval for liver cancer in US
https://pharmaphorum.com/news/bms-pulls-speedy-opdivo-approval-in-liver-cancer-in-us/

Latest News

Pfizer puts up $1bn to buy into Arvinas breast cancer programme

Pfizer has pledged a whopping $1 billion upfront for rights to an Arvinas drug for breast cancer from

Pfizer puts up $1bn to buy into Arvinas breast cancer programme

https://pharmaphorum.com/news/pfizer-puts-up-1bn-to-buy-into-arvinas-breast-cancer-programme/

Arcus’ CMO Grossman jumps ship to join Gilead’s cancer push

Gilead Sciences just forged even closer ties with its cancer drug partner Arcus Biosciences, enticing the biotech’s chief

Arcus’ CMO Grossman jumps ship to join Gilead’s cancer push

https://pharmaphorum.com/news/arcus-cmo-grossman-jumps-ship-to-join-gileads-cancer-push/

BioNTech grows in cell therapies, buying Kite’s TCR platform

BioNTech has found a use for some of the windfall cash it has raked in from its COVID-19

BioNTech grows in cell therapies, buying Kite’s TCR platform

https://pharmaphorum.com/news/biontech-grows-in-cell-therapies-buying-kites-tcr-platform/

See all

Views & analysis

Lessons from the first generation of cell and gene oncology trials

Advances in cell and gene science are paving the way for transformative cancer treatments, but there are still

Lessons from the first generation of cell and gene oncology trials

https://deep-dive.pharmaphorum.com/magazine/oncology-2021/lessons-from-the-first-generation-of-cell-gene-oncology-trials/

Oncology R&D: the patient insights we’re still missing, and how to catch up

Imagine you are a pharma executive working in oncology R&D. The landscape is rapidly becoming more competitive and

Oncology R&D: the patient insights we’re still missing, and how to catch up

https://deep-dive.pharmaphorum.com/magazine/oncology-2021/oncology-rd-patient-engagement/

Digital tools key to immuno-oncology’s future: report

If ASCO 2021 proves anything, it’s that the explosion in immuno-oncology therapies over the last few years shows

Digital tools key to immuno-oncology’s future: report

https://deep-dive.pharmaphorum.com/magazine/oncology-2021/digital-tools-key-to-immuno-oncology-future-report/

See all

Debates & Insights

Cost & Management of Oncology Combination Regimens

Overview Oncology treatment increasingly involves combinations of novel oral and biologic drugs. While combo approaches aren’t new, there

Cost & Management of Oncology Combination Regimens

https://pharmaphorum.com/oncology/cost-management-of-oncology-combination-regimens/

Cancer, genomics and personalised medicine: Modelling oncology’s future

Overview The prevalence of cancer is currently predicted to be higher than ever. Current statistics show 1 in

Cancer, genomics and personalised medicine: Modelling oncology’s future

https://pharmaphorum.com/oncology/cancer-genomics-and-personalised-medicine-modelling-the-future-of-oncology/

11/06/2017

Improving Outcomes Through Industry Partnership – Learnings from the Cancer Vanguard

A unique example of partnership working across the health system, focusses on the service at large, not just the pill, and uses leading-edge data analytics to analyse, benchmark and visualise the current state of the cancer pathways within the Cancer Vanguard Trusts. Furthermore, it encompasses multiple aspects of the service provision ranging from patient outcomes and experiences, the flow of treatment and the usage of medicine in order to inform an evidence-based and patient-centric approach to service redesign and resource optimisation.

Improving Outcomes Through Industry Partnership – Learnings from the Cancer Vanguard

https://pharmaphorum.com/debates-insight-oncology/improving-outcomes-through-industry-partnership-learnings-from-the-cancer-vanguard/

See all

Partner Content

A study to avoid chemotherapy in patients with early HER-2+ breast cancer

Study to improve the life of cancer patients

A study to avoid chemotherapy in patients with early HER-2+ breast cancer

https://pharmaphorum.com/partner-content/a-study-to-avoid-chemotherapy-in-patients-with-early-her-2-breast-cancer/

J+D Forecasting strike the balance for the liquid tumour market

Greater confidence in outputs and decision-making

J+D Forecasting strike the balance for the liquid tumour market

https://pharmaphorum.com/partner-content/jd-forecasting-strike-the-balance-for-the-liquid-tumour-market/

Q&A with SKAN AG speaker released for HPAPI 2020

HPAPI Speaker Interview

Q&A with SKAN AG speaker released for HPAPI 2020

https://pharmaphorum.com/partner-content/qa-with-skan-ag-speaker-released-forhpapi-2020/

See all

Search

Advanced Search

Trending